Company profile
Biopharmaceuticals · Foster City, California, United States · gilead.com
Gilead Sciences is a biopharmaceutical company focused on developing innovative therapeutics for life-threatening diseases, including HIV/AIDS, hepatitis B, hepatitis C, influenza, COVID-19, as well as oncology and inflammation.
Gilead is committed to developing innovative treatments for serious diseases.
Gilead's mission is to discover, develop, deliver innovative therapeutics for people with life-threatening diseases.
Gilead aims to make its therapies accessible globally.
Through partnerships, licensing programs, local collaborations, Gilead expands access to life-saving medicines across the globe.
Gilead seeks to enhance its presence in cancer treatments.
In February 2026, Gilead announced the acquisition of Arcellx, a biotechnology company specializing in oncology treatments, for up to $7.8 billion.
Gilead is focused on improving HIV prevention methods.
In July 2025, Gilead finalized an agreement with the Global Fund to supply lenacapavir for HIV prevention in low- and middle-income countries.
Gilead is integrating advanced technologies to enhance its research and development capabilities.
Gilead's AI initiatives include collaborations with external partners to leverage artificial intelligence in drug discovery.
This is a neutral public preview. Sign in to generate your own personalized brief, with stakeholder angles, talk tracks and where your solution fits, tailored to how you sell.
Generate a full briefYour first brief is free, no card required.
Evidence confidence 85/100. Generated 2026-07-08 from public sources.